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Brain tumours lack metabolic versatility and are dependent largely on glucose for energy. This contrasts with normal brain tissue that
can derive energy from both glucose and ketone bodies. We examined for the first time the potential efficacy of dietary therapies
that reduce plasma glucose and elevate ketone bodies in the CT-2A syngeneic malignant mouse astrocytoma. C57BL/6J mice were
fed either a standard diet unrestricted (SD-UR), a ketogenic diet unrestricted (KD-UR), the SD restricted to 40% (SD-R), or the KD
restricted to 40% of the control standard diet (KD-R). Body weights, tumour weights, plasma glucose, b-hydroxybutyrate (b-OHB),
and insulin-like growth factor 1 (IGF-1) were measured 13 days after tumour implantation. CT-2A growth was rapid in both the SD-
UR and KD-UR groups, but was significantly reduced in both the SD-R and KD-R groups by about 80%. The results indicate that
plasma glucose predicts CT-2A growth and that growth is dependent more on the amount than on the origin of dietary calories.
Also, restriction of either diet significantly reduced the plasma levels of IGF-1, a biomarker for angiogenesis and tumour progression.
Owing to a dependence on plasma glucose, IGF-1 was also predictive of CT-2A growth. Ketone bodies are proposed to reduce
stromal inflammatory activities, while providing normal brain cells with a nonglycolytic high-energy substrate. Our results in a mouse
astrocytoma suggest that malignant brain tumours are potentially manageable with dietary therapies that reduce glucose and elevate
ketone bodies.
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The long-term prognosis remains poor for most patients with
malignant brain tumours despite advances in the molecular
genetics of cancer and in brain imaging techniques (Shapiro,
1999). Surgical resection followed by radiation is the standard
therapy today as it has been for over five decades. Chemotherapy
also has had little positive benefit on malignant glioma manage-
ment and is often associated with adverse effects that diminish
quality of life (Shapiro, 1999). Although therapeutic targeting of
tumour-associated mutations may be effective in tumour manage-
ment, most tumour mutations arise as later stage epiphenomena of
tissue disorganisation and their involvement with tumour initia-
tion, promotion, or progression has not been conclusively
established (Sonnenschein and Soto, 1999, 2000; Seyfried, 2001;
Bergstein, 2003). Clearly, alternative therapies are needed that can
better manage brain tumours while permitting a decent quality of
life.
Metabolic control theory applies principles of bioenergetics for
the control or management of complex diseases (Veech et al, 2001;
Strohman, 2002; Greene et al, 2003). Since metabolism is a
universal process underlying all phenotypes, modification of
metabolism can potentially modify phenotype. The theory is based
on the idea that compensatory genetic and biochemical pathways
regulate the bioenergetic potential of glycolysis, the tricarboxylic
acid (TCA) cycle, and the electron transport chain. This produces a
flexible and versatile metabolic system that is capable of restoring
an orderly adaptive behaviour to widely disordered conditions
involving complex gene–environmental interactions (Greenspan,
2001; Strohman, 2002; Greene et al, 2003). As biological chaos
underlies the progression of brain tumours (Seyfried, 2001),
principles of metabolic control theory may be effective in
managing brain cancer.
In 1995, Nebeling et al reported that a ketogenic diet could
manage advanced stage malignant astrocytoma in two female
paediatric patients (Nebeling et al, 1995). The ketogenic diet (KD)
is a high-fat, low-protein, low-carbohydrate diet that has been used
for decades to treat patients with refractory epilepsies (Freeman
et al, 2000; Todorova et al, 2000; Greene et al, 2003). It was not
clear, however, whether KD controlled paediatric astrocytoma
through effects on plasma glucose or ketone bodies since the diet
was administered under restricted conditions where blood glucose
levels were also reduced (Nebeling et al, 1995). Although the
findings with paediatric astrocytoma generated considerable
interest in the brain tumour field (Nebeling and Lerner, 1995),
no further studies were conducted in humans and no studies have
evaluated the efficacy of this dietary therapy in a brain tumour
animal model.
While brain cells metabolise glucose for energy under normal
physiological conditions, they can metabolise ketone bodies
(acetoacetate and b hydroxybutyrate) for energy when blood
glucose levels decrease as occurs during fasting or caloric
restriction (Owen et al, 1967; Clarke and Sokoloff, 1999; Greene
et al, 2001, 2003). In contrast to glucose, ketone bodies bypass
cytoplasmic glycolysis and directly enter the TCA cycle as acetyl
CoA (Sato et al, 1995; Veech et al, 2001). Gliomas and most tumour Received 22 May 2003; revised 14 July 2003; accepted 15 July 2003
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scells, however, lack this metabolic versatility and are largely
dependent on glycolytic energy (Fearon et al, 1988; Mies et al,
1990; Oudard et al, 1997; Aronen et al, 2000; Roslin et al, 2003).
Defects in ketone body metabolism, the mitochondrial TCA cycle,
and electron transport chain systems are thought to underlie the
dependence of tumour cells on glycolytic energy (Warberg, 1956;
Fredericks and Ramsey, 1978; Tisdale and Brennan, 1983; Lichtor
and Dohrmann, 1986; John, 2001). Hence, therapies that exploit
the genetic and metabolic weakness of brain tumour cells may be
effective in controlling brain cancer.
Dietary caloric restriction (DR) has long been recognised as a
natural therapy that improves health, promotes longevity, and
significantly reduces the incidence, establishment, and growth of
many tumour types (Rous, 1914; Tannenbaum, 1959; Weindruch
and Walford, 1988; Birt et al, 1999; Kritchevsky, 1999a; Duan et al,
2003; Koubova and Guarente, 2003). Dietary caloric restriction is
produced from a total dietary restriction and differs from acute
fasting or starvation in that DR reduces total caloric energy intake
without causing anorexia or malnutrition (Tannenbaum, 1959;
Mukherjee et al, 1999). We recently showed that a moderate DR of
30–40% significantly reduced angiogenesis and growth in the CT-
2A malignant mouse astrocytoma model (Mukherjee et al, 2002).
Moreover, DR significantly increased the number of apoptotic cells
in the CT-2A tumour. We suggested that DR reduced CT-2A
growth through effects on both the tumour cells and on the
tumour-associated host cells. Reduced glycolytic energy together
with a global downregulation of inflammatory and angiogenic
properties of the microenvironment were proposed to underlie the
antitumour effects of DR (Mukherjee et al, 1999, 2002).
In this study, we compared the effects of restricted feeding of a
standard diet or a KD on the orthotopic growth of the CT-2A brain
tumour. While CT-2A growth was rapid with the unrestricted
feeding of either diet, a moderate 40% restriction of either diet
significantly reduced growth. Reductions of plasma glucose
together with elevations of plasma ketones were associated with
the antitumour efficacy of the diets. Also, restriction of either diet
significantly reduced the plasma levels of insulin-like growth
factor-1 (IGF-1), a biomarker for angiogenesis and tumour
progression. Our results in mice suggest that malignant brain
tumours may be manageable in part through dietary reduction of
glucose and elevation of ketone bodies.
MATERIALS AND METHODS
Mice
Mice of the C57BL/6J strain were obtained from Jackson
Laboratory (Bar Harbor, ME, USA). The mice were propagated
in the animal care facility of Department of Biology of Boston
College. Male mice (10–12 weeks of age) were used for the studies
and were provided with food under either ad libitum or
unrestricted (UR) conditions or under restricted (R) conditions
(as below). Water was provided ad libitum to all mice. The animal
room was maintained at 22711C and cotton nesting pads were
provided for additional warmth. All animal experiments were
carried out with ethical committee approval in accordance with the
National Institutes of Health Guide for the Care and Use of
Laboratory Animals and were approved by the Institutional
Animal Care Committee. These procedures also met the standards
required by the UKCCCR guidelines (Workman et al, 1998).
Brain tumour model
The syngeneic CT-2A experimental mouse brain tumour used for
these studies was the second cerebral tumour (CT-2) generated in
our laboratory after implantation of 20-methylcholanthrene into
the cerebral cortex of a C57BL/6J mouse according to the
procedure of Zimmerman (Zimmerman and Arnold, 1941; Seyfried
et al, 1992). Histologically, the CT-2A brain tumour is broadly
classified as a poorly differentiated highly malignant anaplastic
astrocytoma (Seyfried et al, 1992). The tumour grows orthotopi-
cally as a soft, noncohesive, and highly vascularised mass.
Intracerebral tumour implantation
The CT-2A tumour was implanted into the cerebral cortex of
C57BL/6J mice using a trocar as we previously described (Seyfried
et al, 1987; Ranes et al, 2001). Briefly, mice were anaesthetised with
2, 2, 2-tribromoethanol intraperitoneally and their heads were
shaved and swabbed with 70% ethyl alcohol under sterile
conditions. Small CT-2A tumour pieces from a C57BL/6J donor
mouse were matched for size (about 1mm
3) based on a grid and
were implanted into the right cerebral hemisphere of anaesthetised
recipient mice (Ranes et al, 2001). Initiation of tumours from
intact tumour pieces is preferable to initiation from cultured cells
since the pieces already contain an established microenvironment
and vasculature that facilitates rapid tumour establishment and
growth (Tannenbaum, 1959). All of the mice recovered completely
from the surgical procedure and were returned to their cages when
fully active (within 2h). No animals died from either the surgical
procedures or from tumour growth. All mice were euthanised prior
to tumour morbidity.
Diets
All mice received PROLAB chow (Agway Inc.,. NY, USA) prior to
the experiment. This is the standard diet (SD) and contained a
balance of mouse nutritional ingredients. According to the
manufacturer’s specification, this diet delivers 4.4kcalg
 1 gross
energy, where fat, carbohydrate, protein, and fibre comprised 55,
520, 225, and 45gkg
 1 of the diet, respectively. The ketogenic diet
was obtained from Zeigler Bros., Inc. (Gardners, PA, USA) and also
contained a balance of mouse nutritional ingredients. According to
the manufacturer’s specification, the KD delivers 7.8kcalg
 1 gross
energy, where fat, carbohydrate, protein, and fibre comprised 700,
0, 128, and 109gkg
 1 of the diet, respectively. The fat in this diet
was derived from lard and the diet had a ketogenic ratio
(fats:proteinsþcarbohydrates) of 5.48:1.
Dietary restriction
The mice were group housed prior to the initiation of the
experiment and were then housed singly in plastic shoebox cages 1
day before tumour implantation. After tumour implantation, mice
were randomly assigned to one of four diet groups that received
either: (1) the standard diet fed ad libitum or unrestricted (SD-
UR), (2) the KD fed ad libitum or unrestricted (KD-UR), (3) the SD
restricted to 40% (SD-R), or (4) the KD restricted to 40% of the
control standard diet (KD-R). Total dietary restriction maintains a
constant ratio of nutrients to energy, that is, the average daily food
intake (g) for the UR-fed mice was determined every other day and
the R-fed mice were given 60% of the SD-UR group on a daily
basis. This ensured that the mice in both R mouse groups received
a similar number of total calories throughout the study. The
dietary treatments were initiated 24h following tumour implanta-
tion and were continued for 13 days. Body weights of all mice were
recorded every other day.
Tumour growth
Intracerebral tumour growth was analysed directly by measuring
total tumour dry weight. Tumours were dissected from normal
appearing brain tissue, frozen, and then lyophilised to remove
water. From our experience, total tumour dry weight is a more
accurate measure of tumour growth than total wet weight because
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sindividual CT-2A tumours can vary in the degree of haemorrhage
and oedema.
Measurement of plasma glucose and b-hydroxybutyrate
Blood was collected from mice on the last day of the experiment
and before tumour resection. The mice were anaesthetised with
Isoflurane (Halocarbon), and blood was collected from the heart in
heparinised tubes. All mice were fasted for 3h before blood
collection. The blood was centrifuged at 1600 g for 10min, and the
plasma was collected and stored at  801C until assayed. Plasma
glucose and b-hydroxybutyrate (b-OHB) concentrations were
measured spectrophotometrically using the Trinder assay and a
UV enzymatic assay, respectively (Sigma, St Louis, MO, USA). We
measured only b-OHB levels because b-OHB is derived from
acetoacetate in the liver and is the major blood ketone body (Krebs
et al, 1971; Bhagavan, 2002).
Insulin-like growth factor-1 (IGF-1) analysis
Plasma IGF-1 concentrations were measured by radioimmunoas-
say (Nichols Institute Diagnostics, Capistrano, CA, USA) with
purified IGF-1 as the standard and controls supplied by kit as we
previously described (Mukherjee et al, 1999).
Statistical analysis
Body weight, food intake, tumour growth and all serum
quantitative measurements were analysed by ANOVA followed
by Fisher’s PLSD to calculate two-sided pairwise comparison
among different test groups by use of Statview 5.0. In each figure, n
designates the number of individual mice analysed. Error bars in
the figures are expressed as 95% confidence intervals (CIs)
(1.96 standard error of mean) according to the recommended
standards (Streiner, 1996). Linear regression was used to
determine the relationships among plasma glucose, b-OHB, and
tumour growth (Lang and Secic, 1997). The regressions are
expressed as the slope795% CI.
RESULTS
No adverse effects were observed in the 40% R-fed mice that were
maintained on either the SD or the KD. Although total body weight
was reduced, the R-fed mice were healthy and more physically
active than the mice in either UR-fed group. No signs of vitamin or
mineral deficiency were observed in the R-fed mice according to
standard criteria for mice (Hoag and Dickie, 1968). These findings
are consistent with the well-recognised health benefits of mild-to-
moderate diet restriction in rodents (Tannenbaum, 1959; Wein-
druch and Walford, 1988; Keenan et al, 1999). The UR-KD mice
also appeared healthy throughout the study, but displayed oily fur
and stool discoloration (yellowish). The intestinal tract was also
discolored in UR-KD mice upon dissection.
Energy intake
Energy intake increased significantly about 2 days after intracer-
ebral tumour implantation in both UR-fed groups (Figure 1A).
This phenomenon was also observed previously in mice pretreated
with DR for 7 days prior to tumour implantation (Mukherjee et al,
2002). This increased energy intake results from hyperphagia
(binge eating) that may be associated with cerebral hyperglycolysis
following tumour implantation (Gadisseux et al, 1984; Bergsneider
et al, 1997; Mukherjee et al, 2002) . In order to maintain a 40%
dietary restriction throughout the study, energy intake was
increased in the R-fed mice to compensate for the hyperphagia
in the UR-fed mice.
The initial total energy intake of the UR-fed groups was about
11–12kcalday
 1, but rose to about 20kcalday
 1 during the
hyperphagic period (Figure 1A). Energy intake declined in these
mice after about day 9 and returned to the initial intake by day 11.
The reduced energy intake beyond day 11 reflected the effects of
tumour burden. The total energy intake of the R-fed groups was
adjusted to 60% of that in the UR-SD group throughout the study.
Thus, both R-fed groups received similar amounts of total calories
despite differences in the caloric origin of the diets.
The hyperphagia in the UR-fed groups was not associated with a
significant increase in body weight (Figure 1B). A similar finding
was seen in sham-operated mice suggesting that the brain trauma
from tumour implantation increased basal metabolic rate. The R-
fed mice lost about 10% of their initial body weight during the first
week of treatment and their weights remained significantly lower
than those of the UR-fed groups throughout the study (Po0.001).
The body weight decline in the R-fed groups after day 9 reflected
the body weight decline in the UR-fed groups due to increased
tumour burden.
Dietary restrictions reduce intracerebral CT-2A tumour
growth
The intracerebral CT-2A tumour grew rapidly and to a large size in
both groups of UR-fed mice (Figure 2). Restricted feeding of either
the SD or the KD significantly reduced tumour growth. The mean
tumour dry weight was approximately 86% less in the SD-R group
than in the SD-UR group and was approximately 80% less in the
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Figure 1 Energy intake (A) and body weights (B) in male C57BL/6J
mice bearing the intracerebral CT-2A brain tumour. Tumours were
implanted on day 0 and dietary treatment was started on day 1. Values are
expressed as means with 95% confidence intervals, and n¼the number of
tumour bearing mice examined in each group.
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sKD-R group than in the KD-UR group (Figure 2). This growth
reduction in tumour weight greatly exceeded the reduction in the
body weight. It is important to mention that all implanted tumours
grew in both the UR- and R-fed groups suggesting that restricted
feeding of either the SD or the KD did not prevent tumour ‘take’ or
establishment, but significantly reduced the intracerebral growth
of the malignant CT-2A brain tumour.
Influence of diet on plasma glucose and b-OHB levels
Plasma glucose levels were significantly lower in the R-fed mouse
groups than in the UR-fed groups (Table 1). Plasma glucose levels,
however, were similar in both UR-fed mouse groups. These
findings are consistent with previous studies in mice that the KD,
fed ad libitum, does not significantly alter plasma glucose levels
(Todorova et al, 2000). In contrast to glucose levels, b-OHB levels
were two-fold greater in the SD-R mice than in the SD-UR mice
(Table 1). Although the ketone levels in the KD-UR and KD-R
groups were not significantly different, the ketone levels in both
these groups were significantly greater than that in the SD-UR.
These findings are consistent with previous studies in mice that b-
OHB levels are increased under caloric restriction or the KD
(Todorova et al, 2000; Greene et al, 2001).
Statistical analysis of plasma glucose levels, b-OHB levels,
and CT-2A tumour growth
To determine whether blood glucose levels were predictive of
blood b-OHB levels and tumour growth, we analysed the data
using simple linear regression. These statistical analyses also
included one mouse considered an outlier, that is, a mouse that ate
less in the SD-UR group. This mouse also had reduced body weight
and plasma glucose. This outlier was considered restricted for
caloric intake and similar to the mice in R-fed groups. Although
the outlier was excluded from the data presented in Figures 1 and
2, and Table 1, the data from this mouse were included in the
regression analyses in order to assess the relationships between
glucose, b-OHB, and tumour growth.
Simple linear regression analysis was used to examine the
relationship between plasma glucose levels (the independent or
explanatory X variable) and b-OHB levels (the dependent or
response Y variable) for both the SD and the KD. These variables
were identified based on physiological and neurochemical studies
showing that plasma glucose levels determine plasma b-OHB levels
during periods of fasting (Clarke and Sokoloff, 1999; Greene et al,
2001). The assumptions of simple linear regression were met
according to the established criteria (Lang and Secic, 1997). The
slopes of the regression lines were highly significant (Po0.01) and
showed that plasma b-OHB levels increased as glucose levels
decreased for the SD ( 0.14370.074; t¼ 4.22; Y¼2.03–0.143X,
n¼14) and for the KD ( 0.09970.063; t¼ 3.26; Y¼2.028–
0.099X, n¼20). The coefficient of determination (r
2) was greater
in the SD group (0.598) than in the KD group (0.384). This is
expected since ketone levels are higher in the KD-UR mice than in
the SD-UR mice and this would reduce the association. Viewed
together, these findings indicate that plasma b-OHB levels are
dependent on plasma glucose levels and that glucose levels predict
b-OHB levels in both dietary groups.
We next used linear regression to analyse the association
between plasma glucose (the X variable) and CT-2A growth (the Y
variable) for both dietary groups combined (Figure 3). The slope of
the regression line was highly significant (7.96þ2.75; t¼5.90;
Y¼ 23.8477.96X, n¼34) (Figure 3). Thus, plasma glucose levels
were highly significant in predicting CT-2A growth.
Since the above linear regression indicated that b-OHB levels
were dependent on glucose levels, the slope was significant for the
association between CT-2A growth and b-OHB levels in the SD
group (r
2¼0.637), but not for the KD group (r
2¼0.085). Hence,
no association was seen between CT-2A growth and blood ketone
levels (Figure 2 and Table 1) indicating that ketone elevation alone
is unable to reduce growth.
Plasma IGF-1
Circulating IGF-1 levels were significantly lower in each R-fed
mouse group than in the respective UR-fed group (Table 1).
Changes in plasma IGF-1 levels were also associated with changes
in plasma glucose levels (Table 1). Indeed, linear regression
analysis indicated that plasma glucose is predictive of plasma IGF-
1 levels (Figure 4A). The slope of the regression line was significant
and showed that IGF-1 decreased as glucose levels decreased
(15.42711.68; t¼2.74; Y¼92.20þ15.42X). Since plasma glucose
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Figure 2 Influence of diet on the intracerebral growth of the CT-2A
brain tumour. Dietary treatment was initiated 1 day after tumour
implantation and was continued for 13 days as shown in Figure 1. Tumour
weights were measured in C57BL/6J mice receiving either the standard diet
(SD) or ketogenic diet (KD) under either unrestricted (UR) or restricted
(R) feeding. Values are expressed as means with 95% CIs, and n¼the
number of mice examined in each group. The dry weights of the tumours
in R groups were significantly lower than those in the UR groups at Po0.01.
Table 1 Influence of diet on plasma glucose, b-OHB, and IGF-1 levels in
mice bearing the CT-2A intracerebral brain tumour
a
Diet
b Groups
c
Glucose
(mmoll
 1)
b-OHB
(mmoll
 1)
IGF-1
(ngml
 1)
SD UR 9.170.9 0.670.1 208725
(7)
d (7) (6)
R 5.271.1* 1.470.2* 117736*
(6) (6) (6)
KD UR 11.471.4 1.070.3 294730
(14) (14) (5)
R 5.771.5* 1.370.6 193757*
(6) (6) (6)
aValues are expressed as means 795% confidence intervals as described in Materials
and Methods.
bAnimals were fed either a standard chow diet (SD) or a ketogenic diet
(KD).
cUR (unrestricted feeding) and R (restricted to 60% of the SD-UR group as
described in Materials and Methods).
dNumbers in parentheses indicate the number
of independent tumour-bearing mice examined in each group. The asterisks indicate
that the values of the R groups differed from those of their respective UR groups at
Po0.01 (analysed by ANOVA, one-way).
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slevels are predictive of both tumour growth and IGF-1 levels, we
next analysed the relationship between plasma IGF-1 levels and
CT-2A tumour growth (Figure 4B). The slope of this regression
line was also significant and showed that CT-2A tumour growth
decreased as IGF-1 levels decreased (0.2070.02; t¼2.43;
Y¼ 6.84þ0.20X). These findings indicate that plasma IGF-1,
like plasma glucose, is predictive of CT-2A growth.
DISCUSSION
Normal mammalian brain cells are metabolically versatile and
capable of deriving energy from glucose and ketone bodies
(Greene et al, 2003). Although the levels of glucose and ketones
in brain are proportional to their levels in blood, the adult brain
does not usually metabolise ketones for energy under normal
physiological conditions (Clarke and Sokoloff, 1999; Laterra et al,
1999; Guzman and Blazquez, 2001; Bhagavan, 2002). The brain will,
however, actively metabolise ketone bodies for energy if blood
glucose levels are reduced. We recently showed that circulating
ketone levels are inversely related to circulating glucose levels in
calorie restricted epileptic mice (Greene et al, 2001). The results of
the present study support these previous findings. Ketone bodies
bypass cytoplasmic glycolysis and directly enter the TCA cycle as
acetyl CoA (Nehlig and Pereira de Vasconcelos, 1993; Sato et al,
1995; Kashiwaya et al, 2000; Veech et al, 2001). This causes
significant increases in the TCA cycle metabolites and improves
physiological performance through an increase in the energy of
ATP hydrolysis (Sato et al, 1995; Veech et al, 2001).
We suggest that the metabolic mechanism by which moderate
DR inhibits CT-2A brain tumour growth involves a failure to
utilise alternative energy substrates. Most tumours including
primary brain tumours actively consume glucose and are largely
dependent on glycolysis for energy (Warberg, 1956; Galarraga et al,
1986; Mies et al, 1990; Oudard et al, 1997; Roslin et al, 2003).
Mitochondrial defects and an inability to metabolise ketone bodies
are thought to be responsible for the dependence of tumour cells
on glycolytic energy (Warberg, 1956; Fredericks and Ramsey, 1978;
Pedersen, 1978; Tisdale and Brennan, 1983; Lichtor and Dohr-
mann, 1986; Oudard et al, 1997; John, 2001). The flexibility and
versatility of gene-linked metabolic network interactions in
response to alterations in nutritional environment underlies
metabolic control theory (Greenspan, 2001; Veech et al, 2001;
Strohman, 2002; Greene et al, 2003). As DR inhibits glycolysis, DR
would force cells to switch from glucose to alternative noncarbo-
hydrate energy metabolites, for example, ketones (Greene et al,
2003; Hagopian et al, 2003). While this switch occurs readily in
normal cells, the switch is more difficult for tumour cells due to
their accumulated genetic defects. Our results in the CT-2A
astrocytoma support the feasibility of metabolic control for the
management of brain cancer.
CT-2A growth reduction was associated with reduced blood
glucose levels. Indeed, linear regression analysis showed that blood
glucose levels were predictive of CT-2A growth. Although blood
ketone levels were elevated under restriction of either diet, elevated
ketone levels alone could not account for reduced tumour growth
because tumour growth was rapid in the UR-KD group despite the
presence of high ketone levels. These findings support the previous
observations of Fearon et al (1985), who showed that the failure of
a KD to restrict growth of the Walker 256 rat tumour resulted from
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Figure 3 Linear regression analysis of plasma glucose and CT-2A-
tumour growth in mice from both the SD and KD dietary groups combined
(n¼34). These analyses included the values for plasma glucose and tumour
growth of individual mice from both the UR- and R-fed groups. The linear
regression was highly significant at *Po0.001.
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Figure 4 Linear regression analysis of plasma glucose and IGF-1 levels
(A), and plasma IGF-1 levels and CT-2A-tumour growth (B) in mice fed
with both the SD and KD (n¼23). These analyses included the values for
plasma glucose and b-OHB levels of individual mice from both the UR- and
R-fed groups. The linear regressions were highly significant at Po0.01.
Dietary management of brain cancer
TN Seyfried et al
1379
British Journal of Cancer (2003) 89(7), 1375–1382 & 2003 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sthe failure of ketosis to reduce glucose availability. Moreover,
reduced blood glucose was associated with the management of
advanced stage malignant astrocytoma in two female paediatric
patients with the KD (Nebeling and Lerner, 1995; Nebeling et al,
1995). Hence, reduced glucose is a key factor in the metabolic
control of the mouse CT-2A tumour and possibly human
paediatric astrocytoma.
If the antitumour effects of restricted caloric intake are
associated with reduced glucose levels and glycolytic energy, a
question arises as to what role elevated ketone levels might have in
CT-2A management. We suggest that ketone body metabolism,
while providing normal brain cells with an alternative high-energy
substrate, also reduces the inflammatory activities of tumour-
associated host cells (stromal cells). Ketone body metabolism
reduces oxygen free radicals, enhances tolerance to hypoxia, and
may prevent organ dysfunction from inflammatory processes
(Kirsch and D’Alecy, 1984; Yu et al, 1990; Marcondes et al, 2001;
Veech et al, 2001; Sharman et al, 2002). Indeed, Dong et al (1998)
reported that moderate caloric restriction could reduce the
proinflammatory properties of macrophages while enhancing their
phagocytic function. Activated macrophages also contribute to
tumour angiogenesis that is reduced under DR (Mukherjee et al,
1999, 2002). Uncoupling the detrimental inflammatory activities of
macrophages from their potentially beneficial phagocytic activities
is considered important for the eventual management of brain
cancer (Seyfried, 2001). Hence, a shift in energy metabolism from
glucose to ketones will enhance the bioenergetic potential of
normal brain cells on the one hand while reducing tumour cell
growth and tumour inflammatory properties on the other hand.
Insulin-like growth facor-1 is considered a biomarker for
angiogenesis and tumour progression (Kari et al, 1999; Mukherjee
et al, 1999; Yu and Rohan, 2000). Besides predicting CT-2A growth,
we found that plasma glucose also predicts plasma IGF-1 levels.
These observations agree with previous studies that glucose
regulates IGF-1 expression (Straus and Burke, 1995; Wang et al,
2000). We recently presented histological evidence that moderate
dietary restriction significantly reduces vascularity (angiogenesis)
in the CT-2A brain tumour (Mukherjee et al, 2002). Our findings
that moderate restriction of either the SD or the KD reduced
circulating IGF-1 levels support further the antiangiogenic effects
of DR. Since plasma IGF-1 and glucose are both predictive of CT-
2A tumour growth, we suggest that either glucose or IGF-1 may be
useful biomarkers for predicting the effects of DR on brain tumour
growth and angiogenesis.
In addition to reducing angiogenesis, moderate DR also
enhances apoptosis in the CT-2A tumour and in prostate cancer
(Mukherjee et al, 1999, 2002). This is the interesting in light of
recent findings that the glycolysis inhibitor 2-deoxy-D-glucose or
glucose deprivation enhances apoptosis in human breast and lung
cancer cells (Lee et al, 1997; Shim et al, 1998; Aft et al, 2002). Since
DR also reduces blood glucose levels, it is possible that DR reduces
CT-2A tumour growth through glucose-dependent apoptotic
pathways similar to those seen in other tumours (Shim et al,
1998; Aft et al, 2002). Further studies will be needed to test this
hypothesis.
In contrast to the situation with prostate cancer and other non-
neural cancers (Tannenbaum, 1959; Bosland et al, 1999; Kritch-
evsky, 1999b; Mukherjee et al, 1999), little is known about the
influence of diet on the progression of brain cancer. We found that
orthotopic growth of the CT-2A brain tumour was similarly rapid
during the unrestricted feeding of either a standard laboratory diet
or a high-fat KD suggesting that a high-fat diet does not
significantly enhance growth over that of a standard diet fed ad
libitum. On the other hand, CT-2A growth was significantly
reduced when either diet was restricted to 60% of the control diet.
These findings indicate that orthotopic CT-2A brain tumour
growth, like prostate tumour growth, is influenced more by the
amount of dietary calories than by the origin or source of the
calories (Tannenbaum, 1959; Mukherjee et al, 1999). Hence, diet
and lifestyle may influence the progression of brain cancer.
An issue not addressed in this study is whether restricted
feeding of either the SD or the KD would extend the survival of the
CT-2A tumour-bearing mice. Survival studies are difficult with this
rapidly growing brain tumour model because intracranial pres-
sure, which often causes morbidity in brain tumour patients, is
relieved due to skull expansion or tumour growth through the
implantation burr hole (Mukherjee et al, 2002). This makes
estimates of longevity capricious. Although the overall health was
better in the R-fed mice than in the UR-fed mice, further studies
will be necessary to determine if DR would extend survival.
In summary, our results suggest that experimental brain cancer
is manageable through principles of metabolic control where
plasma glucose levels are reduced and ketone body levels are
elevated. Dietary energy restriction reduces tumour growth
through effects on angiogenesis, apoptosis, and inflammation.
Moreover, this dietary therapy may be effective for brain cancer
management in humans and can be designed according
to established standards (Nebeling and Lerner, 1995; Freeman
et al, 2000). Body weight reductions of 10–12% should
not adversely affect development or other functions in children
as long as rate of weight gain is maintained (Nebeling and Lerner,
1995; Freeman et al, 2000; Greene et al, 2001). We also previously
suggested that DR could reduce tumour-derived levels of
procachexic factors by reducing tumour size (Mukherjee et al,
2002). Dietary caloric restriction may also be effective against
recurrent human gliomas or could be used as an adjuvant with
radiation or chemotherapy. We contend that dietary therapy may
improve the clinical outcome of brain tumour patients and
enhance their quality of life.
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